Stem Pharm的动态

Biotech is heating up after a frosty period! Several startups, especially those focusing on cancer and weight loss research, have seen substantial investment, with some even raising hundreds of millions of dollars. This surge in funding marks a promising start to the year for an industry that faced challenges in recent times. Despite a slowdown in the past two years due to various factors, including interest rate hikes and market uncertainties, biotechs are now attracting significant capital. With venture capitalists pouring billions into the sector and a flurry of IPOs, including CG Oncology and ArriVent BioPharma, the industry is regaining momentum. Investors are particularly interested in companies with advanced drug treatments and those exploring cutting-edge areas like nonopioid pain treatment.? #biotech #investmentopportunities #innovation

Global Digital Therapeutics (DTx) Startup Ecosystem: Deep Dive Analysis Through an extensive search and review of publicly available information, 172 startups were selected for detailed analysis based on specific criteria: Business Profile, Product, Technological Innovation including Patents, Investment and Fund Raising, Key Leadership, Revenue, Market, Clinical Trials, and Reimbursement Contents Global DTx Startup Landscape 1.5Q 2024 Global DTx Startups' Key Target Health Conditions 1.5Q 2024? Global DTx Product Landscape 1.5Q 2024? Global DTx Innovation (Patent) Landscape 1.5Q 2024 Partnerships between DTx Startups and Pharmaceuticals & Clinics 1.5Q 2024 Global DTx Startup Fund Raising Cases 1.5Q 2024 Conundrum in DTx Ecosystem Future of Global DTx Ecosystem Analysis Samples Expert invitation for comment: Koen Kas Tony J Simon, Ph.D. Kelly Stein-Marcus Marguerite Manteau-Rao, LCSW, MBA Janvi Parmar Ravi Janapureddy Howard Berman, PhD Seth Feuerstein Torsten Schr?der, MD, PhD Logan Harper Stephen Hamm, MBA Bikram Gangwar Micha?l Cardinal Sean G.(Sungjee) Kang, MD, MPH Robert A. Renata Redondo Bonaldi, PhD, Global MBA Ian Miller Jon Redmond Joshua Bull Klaudia Dobrev Marcelo Duhalde #digitaltherapeutics #dtx #startup #product #innovation #patent #fundraising #ecosystem?

The resurgence in US biotech funding is a beacon of hope, not just for the industry, but for the global health ecosystem.?? At Adelphi Ventures, we believe that the right guidance can turn potential into reality. We're committed to nurturing early-stage biotech startups poised for market disruption. Let's innovate together and shape a healthier future. Reference: Labiotech - Will the US biotech funding surge trigger a renaissance in the global biotech industry? https://lnkd.in/egbvRwbC #BiotechBoom #EarlyStageInnovation #MarketDisruption #AdelphiVentures #HealthTech #StartupGrowth #InvestmentOpportunity #USBiotech #BioEcosystem #SustainableHealth #MedicalAdvancements #TechInvesting #LifeSciences #BiotechFunding #HealthcareInnovation #VentureCapital #Biomedical #GlobalHealthImpact #ScienceAndTechnology #FutureOfHealthcare

????Austrian Biotech Innovators With Austria’s biotech ecosystem continually evolving, its contribution to global healthcare is set to grow exponentially. From breakthrough therapies to cutting-edge diagnostics, early-stage startups are pushing the boundaries of what’s possible. Backed by a robust ecosystem of academia, government, and industry collaboration, these innovators are setting the stage for the next big leap in healthcare. But it’s not just about invention—it’s about impact. These startups are tackling some of the world’s most pressing health challenges, striving to cut costs, improve patient outcomes, and expand treatment access on a global scale. ?? Read more about the Top 10 Early-Stage Life Sciences/Biotech Startups reshaping the future: https://lnkd.in/gF4pibuy ? Featured Startups: ? Sarcura – Daniela Buchmayr, Erwin Gorjup (Cell therapy manufacturing) ? HeartBeat.bio AG – Michael Krebs, Florian Fuchs (Cardiac drug discovery) ? a:head bio AG – Oliver Szolar, Madeline Lancaster (CNS drug discovery) ? VALANX Biotech – Michael Lukesch (Protein conjugation) ? Cellectric Biosciences – Terje Wimberger, Klemens Wassermann(Precision diagnostics) ? Biolyz – Marlon Millard (Non-invasive analytics) ? Solgate – Ariel Bensimon, Giulio Superti-Furga, Stefan Kubicek, and Georg Winter (Metabolic disease targeting) ? HD Immune – Stefan Bartl, Lionel Wightman (Huntington’s treatment) ? Phoenestra GmbH – Klaus Graumann(Cell therapy bioprocessing) ? Luminous Labs – Barbara Sekulovska, Thomas Lechner (Red light therapy) ? Key Investors Supporting BioTech Innovation: XYZ Ventures | xista science ventures | Nina Capital |CTI Life Sciences Fund | Tensor Ventures | Atrinum. Ventures AG | Austria Wirtschaftsservice | Austrian Angel Investor Association (aaia) ?? Explore more such startups on Zefyron's Startup and Investor Database : bit.ly/Zefyron ???Sign up for FREE: bit.ly/ZefyronFree #BiotechInnovation #LifeSciences #Healthcare #AustrianStartups

?? Registrations are now open for #GenAI4Pharma: #Cambridge (USA). Please join us at the Insilico Medicine office in Cambridge, MA, where Carol Ann Satler, (VP, Clinical Development @ Insilico Medicine) will discuss the recent Phase IIa results form their novel #GenerativeAI-designed drug treatment for #IPF. ? #Location: Cambridge, MA (USA) ? #Date: December 12th, 2024 ? #Registration: https://lu.ma/hn9mku85 ? #Details: https://lnkd.in/ezJEifMK The full agenda will be updated soon — don't miss your chance to learn from and network with: #ThoughtLeaders, #BioPharma #Executives, #GenAI #Startups, #Investors, and more. ?? #CallForStartups: If you are a startup working on a hashtag #GenAI / #LLM solution for the #biopharma industry, apply to pitch your startup in front of an audience of biopharma executives, investors, tech companies, startups, consultants, etc.: https://lu.ma/hn9mku85. ?? #SponsorshipOpportunities: We're looking for like-minded event partners, interested in showcasing the transformative power of #GenAI in the biopharma industry, so if you're interested in sponsoring the event, please DM me. cc: Thomas L., Sooah Cho, Alex Zhavoronkov, Petrina Kamya, Ph.D.

We are getting there! Thanks for the mention, Zefyron. Humbling and exciting to see that 1) Health in general is getting more and more prime time attention ? 2) #longevityNOW interventions like ours at Luminous Labs are now getting the spotlight and bigger masses are beginning to understand what it needs in healthspan and lifespan enhancement to succeed. ? . As Sergey Young says, there are four horizons in longevity: diagnostics, prevention, intervention and reversal. . So far, longevity is mainly seen as moonshots; hardcore biotechs and reversal actions that should make us live forever, maybe. Now this is changing and that is GREAT, and it is an honour for us at Luminous Labs to really be seen for what we do. . We are biotech at core, but in a way that already enables humans to experiment and experience our technology in the now; non-invasive, low risk and with so much more potential to explore. ?? . Solving mitochondrial dysfunction one step at a time. ?? Thanks for the support BIOGENA GROUP Science Park Graz (SPG) Steirische Wirtschaftsf?rderung SFG FFG Austrian Research Promotion Agency And to all the ones that are on the journey with us BEYOND GENOMiX Maximon - The Longevity Company Builder Longevity Investors and many many more

?? Fundraising by healthcare startups in the first half of July ?? #Biotech ???? Overseed: develops and manufactures medical cannabis-based therapeutic products ?? Amount raised: €6.7M in Series A ?? Investors: Blast Club, UI Investissement, Groupe Crédit Agricole & Bpifrance ???? Element Biosciences: DNA sequencing and multiomics technologies ?? Amount raised: €255M in Series D ?? Investors: Wellington Management, Samsung Electronics, Fidelity Investments & Foresite Capital ???? SciRhom: biotech specializing in autoimmune diseases ?? Amount raised: €63M in Series A ?? Investors: Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital & Wellington Management ???? Cellaven: develops a specialized PLC for in vitro cell culture ?? Amount raised: €2.8M in seed ?? Investors: Finovam Gestion, Bpifrance & BAs ???? Next Neurotech: solution dedicated to the diagnosis and surgical treatment of drug-resistant epilepsy ?? Amount raised: €750k in seed ?? Investors: Calyseed & SOFILARO / CALEN #DigitalHealth ???? Sidecar Health: group health insurance platform ?? Amount raised: €150M in Series D ?? Investors: Koch Industries, GreatPoint Ventures, BOND, Cathay Innovation, Drive Capital, Duke University, Menlo Ventures & Morpheus ???? SPOTLIGHT MEDICAL: spin-off from Institut Curie, which is developing an AI that aims to predict the effectiveness of cancer patients' response to treatment ?? Amount raised: €6.2M seed ?? Investors: Kurma Partners & Heal Capital ???? Kiwee.care: specialized in simplifying and securing the payment of benefits for healthcare players ?? Amount raised: €1.7M in seed ?? Investors: BA’s #Medtech ???? UroMems: develops an implant designed to treat urinary incontinence ?? Amount raised: €44M in Series C ?? Investors: Crédit Mutuel Innovation & PCN Conseil européen de l'innovation (EIC) More than 60% of startups raised are French ?????? And nearly half a billion euros were raised over the first two weeks of July, led mostly by massive investments in Biotech included Element Biosciences ??

PharmStars’ startups recently had the opportunity to learn firsthand that not all #pharma companies are created equal.?Unlike many other pharma, Novo Nordisk is unique -- it started as a foundation.?While it is publicly traded today, it is still a purpose-driven company that retains and nurtures a value-based culture. Our startups learned about this when our CEO, Naomi Fried, was joined by innovation leaders from Novo, Vanessa Roknic and Ashlee Bessolo, for an intimate Fireside Chat in front of PharmStars' current cohort of startups seeking to engage pharma.?These dynamic leaders shared insights into digital health at Novo Nordisk.?While molecular innovation has long been a focus, Novo Nordisk’s appetite is increasing for digital health solutions. They are focused on opportunities to improve patient identification, education and support, and (of course) patient outcomes. Thank you, Vanessa and Ashlee, for sharing your time with our startups in advance of meeting them next month.?We are looking forward to welcoming you and the full Novo Nordisk delegation at our Showcase Event in Boston soon! #Startup #Accelerator #DigitalHealth #pharma #biopharma #innovation #acceleratorprogram

?????????? ???????? ???????????????? ???????????????? ???????? ???????????????????????????? $?????? ?????????????? ???????? ???? ???????????? ?????????????????????? ?????????????? ?????????????????? Scion Life Sciences Scion Life Sciences, based in NYC and led by seasoned partners Samuel W. Hall Sam Hall, PhD, Aaron M. Kantoff Aaron Kantoff, and Tadd S. Wessel Tadd Wessel of Petrichor Petrichor, announces the final close of its inaugural fund. With a mission to develop transformative medicines, Scion is committed to founding and nurturing biotech startups. Scion's approach focuses on mature therapeutic modalities, deep scientific understanding, and addressing clinical needs with independent resources. The firm's strategic pillars mitigate risk and increase the likelihood of delivering life-changing treatments. "We're dedicated to solving critical clinical challenges and providing long-term support to build sustainable biotech companies," says Sam Hall Sam Hall, PhD. Scion has already initiated investments in four promising startups and established Scion Innovations to enhance R&D capabilities. This proactive, data-driven approach aims to create impactful medicines and sustainable companies. "We prioritize creating significant new medicines over exits," says Aaron Kantoff Aaron Kantoff. "Our approach, combined with a long-term fund structure, positions us to build biotech companies capable of transforming patient lives." "We're grateful for the trust of our partners who share our vision for impactful medicine creation," adds Tadd Wessel Tadd Wessel . #Biotech #VentureCapital #Investment #Medicine #ClinicalResearch #Biotechnology #Pharmaceuticals #TransformativeMedicine #DrugDevelopment #HealthTech #Entrepreneurship

Clinical trials are crucial in advancing new therapies as they evaluate the safety and efficacy of experimental treatments and ensure they meet regulatory standards. They provide essential data leading to improved patient care and innovative healthcare solutions. To encourage clinical trial investor funding, biotech startups can employ various strategies.? In the recent Clinical Leader article, LongeVC’s Sergey Jakimov and Artem A. Trotsyuk discuss two of them: trial-specific fundraising and staged funding release. Read more here: https://lnkd.in/gy45xt_P. #Biotech #ClinicalTrials #Investing #BiotechInvesting #Startups